4.7 Review

miR-21: a non-specific biomarker of all maladies

Journal

BIOMARKER RESEARCH
Volume 9, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s40364-021-00272-1

Keywords

microRNA; miR-21-5p; Biomarker; Plasma; Serum; cancer; Heart disease

Funding

  1. National Institutes of Health [1R01HL137811, R01GM130564]

Ask authors/readers for more resources

miRNA-21 is considered as a specific predictive or prognostic biomarker for at least 29 diseases, but lacks specificity for any one disease, thus making it not an ideal candidate for a biomarker despite continued evaluation. This issue of non-specificity in biomarker designation is shared with other common, ubiquitous miRNAs and warrants concern for their use as biomarkers as well.
miRNA-21 is among the most abundant and highly conserved microRNAs (miRNAs) recognized. It is expressed in essentially all cells where it performs vital regulatory roles in health and disease. It is also frequently claimed to be a biomarker of diseases such as cancer and heart disease in bodily-fluid based miRNA studies. Here we dissociate its contributions to cellular physiology and pathology from its potential as a biomarker. We show how it has been claimed as a specific predictive or prognostic biomarker by at least 29 diseases. Thus, it has no specificity to any one disease. As a result, it should not be considered a viable candidate to be a biomarker, despite its continued evaluation as such. This theme of multiple assignments of a miRNA as a biomarker is shared with other common, ubiquitous miRNAs and should be concerning for them as well.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available